DPH.L - Dechra Pharmaceuticals PLC
| Previous close | 2,868.00 |
| Open | 2,884.00 |
| Bid | 2,866.00 x 0 |
| Ask | 2,870.00 x 0 |
| Day's range | 2,862.00 - 2,888.00 |
| 52-week range | 1,992.00 - 3,180.00 |
| Volume | 5,706 |
| Avg. volume | 212,656 |
| Market cap | 2.944B |
| Beta (3Y monthly) | 0.51 |
| PE ratio (TTM) | 118.51 |
| EPS (TTM) | 24.20 |
| Earnings date | 2 Sep 2019 |
| Forward dividend & yield | 0.28 (0.96%) |
| Ex-dividend date | 2019-03-07 |
| 1y target est | 2,680.86 |
- Simply Wall St.•24 days ago
Are Dechra Pharmaceuticals PLC (LON:DPH) Investors Paying Above The Intrinsic Value?
Today we will run through one way of estimating the intrinsic value of Dechra Pharmaceuticals PLC (LON:DPH) by...
- Simply Wall St.•24 days ago
Does This Valuation Of Dechra Pharmaceuticals PLC (LON:DPH) Imply Investors Are Overpaying?
Does the June share price for Dechra Pharmaceuticals PLC (LON:DPH) reflect what it's really worth? Today, we will...
- Simply Wall St.•2 months ago
Announcing: Dechra Pharmaceuticals (LON:DPH) Stock Increased An Energizing 287% In The Last Five Years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- Simply Wall St.•2 months ago
Is Dechra Pharmaceuticals PLC's (LON:DPH) ROE Of 4.9% Concerning?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Simply Wall St.•3 months ago
Is Dechra Pharmaceuticals PLC's (LON:DPH) CEO Paid At A Competitive Rate?
In 2001 Ian Page was appointed CEO of Dechra Pharmaceuticals PLC (LON:DPH). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we will consider...
- Reuters - UK Focus•4 months ago
BUZZ-Dechra Pharma: "Diamond in the Ruff" - JPM starts with OW
** JP Morgan starts UK-based animal health co Dechra Pharmaceuticals with "overweight" and PT 3,000p ** Brokerage sees Animal Health as attractive subsector offering strong demographic demand, ...
- Reuters - UK Focus•5 months ago
Ex-divs to take 21.7 points off FTSE 100 on March 7
The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the latest dividend payout. According to Reuters calculations at current market prices, ...
- Simply Wall St.•6 months ago
Should Dechra Pharmaceuticals PLC (LON:DPH) Be Part Of Your Income Portfolio?
Dividends play an important role in compounding returns in the long run and end up forming a sizeable part of investment returns. Historically, Dechra Pharmaceuticals PLC (LON:DPH) has paid dividends Read More...
- Simply Wall St.•7 months ago
Read This Before Buying Dechra Pharmaceuticals PLC (LON:DPH) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have Read More...
- Simply Wall St.•7 months ago
Is Dechra Pharmaceuticals PLC’s (LON:DPH) ROE Of 7.1% Concerning?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
- Simply Wall St.•8 months ago
What Do Analysts Think About Dechra Pharmaceuticals PLC’s (LON:DPH) Earnings Trajectory?
The latest earnings announcement Dechra Pharmaceuticals PLC (LON:DPH) released in June 2018 indicated that the business benefited from a robust tailwind, leading to a double-digit earnings growth of 38%. Investors Read More...
- Simply Wall St.•9 months ago
Is Dechra Pharmaceuticals PLC’s (LON:DPH) CEO Paid Enough Relative To Peers?
In 2001 Ian Page was appointed CEO of Dechra Pharmaceuticals PLC (LON:DPH). First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth that Read More...
- Reuters - UK Focus•9 months ago
Ex-divs to take 1.3 points off FTSE 100 on Oct 25
The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the latest dividend payout. According to Reuters calculations at current market prices, ...
- Simply Wall St.•10 months ago
Does Dechra Pharmaceuticals PLC’s (LON:DPH) PE Ratio Warrant A Sell?
I am writing today to help inform people who are new to the stock market and want to learn about the link between company’s fundamentals and stock market performance. Dechra Read More...
- Simply Wall St.•11 months ago
Is Dechra Pharmaceuticals plc (LON:DPH) Expensive For A Reason? A Look At The Intrinsic Value
Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Dechra Pharmaceuticals plc (LON:DPH) as an investment opportunity by taking theRead More...
- Reuters•11 months ago
European shares flat amid trade and emerging market worries
European shares ended little changed on Monday as worries about U.S. trade policy and concern over emerging markets weighed on stocks after Asian markets closed lower. The pan-European STOXX 600 (.STOXX) index gained 0.05 percent to 382.46 points. Activity was subdued as U.S. markets were closed for Labor Day.
- The Telegraph•11 months ago
Dechra's shares slump as it warns of costs for Brexit contingency plans
Dechra's shares slump as it warns of costs for Brexit contingency plans
- Bloomberg•11 months ago
U.K. Pet Drugmaker Dechra Sparks Share Tumble With Brexit Plans
Dechra Pharmaceuticals Plc, a maker of animal medicines, is looking at setting up dual testing facilities in the U.K. and European Union in preparation for Brexit, a sign companies are stepping up their contingency plans as politicians stumble over a future deal. The veterinary company sparked concern on Monday when it said it may need to spend as much as 2 million pounds ($2.6 million) in the event of a hard Brexit, in part to duplicate testing and move product registrations to the EU to avoid trade barriers. Most companies in the U.K. are preparing contingency plans as the British government and EU officials struggle to reach a deal over what their future relationship will look like.
- Reuters•11 months ago
Dechra Pharma says to implement hard Brexit plan
The company listed Brexit along with U.S. sanctions on Iran and the European Union challenging the legality of the UK Control Foreign Company (CFC) tax legislation as three emerging geopolitical risks to its business. Results for the FTSE 250-listed firm showed revenue rose 13.9 percent to 407.1 million pounds at constant currency for the year-ended June 30.
- Reuters - UK Focus•11 months ago
UK's Dechra Pharma says to implement hard Brexit plan
Veterinary drugs producer Dechra Pharmaceuticals said on Monday it was moving ahead with plans for a hard Brexit, stressing the financial impact should be "immaterial" but spooking investors worried about revenue and operations after next year's split. Shares (Berlin: DI6.BE - news) of the company plunged around 20 percent to a more than six-month low to 2,454 pence in early trading on the London Stock Exchange. "This includes transferring UK registered Marketing Authorisations for products that are sold in the EU to an EU entity and duplication of product release testing for products that are transferred between the UK and the EU," it said.
